RPS10 Gene - Ribosomal Protein S10

RPS10 Gene - Ribosomal Protein S10

<div class="infobox infobox-gene">
<h3>RPS10</h3>
<table>
<tr><th>Full Name</th><td>Ribosomal Protein S10</td></tr>
<tr><th>Gene Symbol</th><td>RPS10</td></tr>
<tr><th>Chromosomal Location</th><td>6p21.33</td></tr>
<tr><th>NCBI Gene ID</th><td>[6204](https://www.ncbi.nlm.nih.gov/gene/6204)</td></tr>
<tr><th>OMIM</th><td>[603642](https://www.omim.org/entry/603642)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000124614</td></tr>
<tr><th>UniProt</th><td>[P46784](https://www.uniprot.org/uniprot/P46784)</td></tr>
<tr><th>Protein Length</th><td>165 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>[Diamond-Blackfan Anemia](/diseases/diamond-blackfan-anemia), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)</td></tr>
</table>
</div>

Introduction

The RPS10 gene encodes Ribosomal Protein S10, a fundamental component of the 40S small ribosomal subunit. As part of the protein synthesis machinery, RPS10 plays essential roles in translation initiation, elongation, and termination within all eukaryotic cells. Mutations in RPS10 were first identified as causative for Diamond-Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome, demonstrating the critical importance of ribosomal proteins in human health and development[@drapt1999][@dekeersmaecker2012].

RPS10 Gene - Ribosomal Protein S10

<div class="infobox infobox-gene">
<h3>RPS10</h3>
<table>
<tr><th>Full Name</th><td>Ribosomal Protein S10</td></tr>
<tr><th>Gene Symbol</th><td>RPS10</td></tr>
<tr><th>Chromosomal Location</th><td>6p21.33</td></tr>
<tr><th>NCBI Gene ID</th><td>[6204](https://www.ncbi.nlm.nih.gov/gene/6204)</td></tr>
<tr><th>OMIM</th><td>[603642](https://www.omim.org/entry/603642)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000124614</td></tr>
<tr><th>UniProt</th><td>[P46784](https://www.uniprot.org/uniprot/P46784)</td></tr>
<tr><th>Protein Length</th><td>165 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>[Diamond-Blackfan Anemia](/diseases/diamond-blackfan-anemia), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)</td></tr>
</table>
</div>

Introduction

The RPS10 gene encodes Ribosomal Protein S10, a fundamental component of the 40S small ribosomal subunit. As part of the protein synthesis machinery, RPS10 plays essential roles in translation initiation, elongation, and termination within all eukaryotic cells. Mutations in RPS10 were first identified as causative for Diamond-Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome, demonstrating the critical importance of ribosomal proteins in human health and development[@drapt1999][@dekeersmaecker2012].

Beyond its well-established role in DBA, emerging research has revealed connections between RPS10 dysfunction and neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). Ribosomal proteins are increasingly recognized as important players in neuronal homeostasis, synaptic plasticity, and the cellular stress responses that go awry in neurodegeneration[@khodorov2012].

Overview

RPS10 is a highly conserved ribosomal protein that participates in multiple aspects of ribosome function. The protein is located at the interface between the 40S head and body domains, where it contacts both the 18S rRNA and several other ribosomal proteins. This strategic position allows RPS10 to influence multiple steps in translation[@gerrish2000].

The identification of RPS10 mutations as a cause of DBA in 2012 represented a major advance in understanding the genetics of this disorder[@dekeersmaecker2012]. DBA is characterized by impaired erythropoiesis, with patients presenting with anemia, often in infancy. Remarkably, although RPS10 is required for ribosome function in all cells, DBA mutations preferentially affect erythropoiesis, suggesting cell-type-specific vulnerabilities in ribosomal function.

In recent years, research has expanded beyond DBA to examine RPS10's broader roles in cellular biology and disease. Studies have revealed connections to p53 signaling, translational control, and cellular stress responses that are relevant to cancer, aging, and neurodegeneration[@mills2014][@martin2017].

Molecular Function

Protein Structure

RPS10 is a 165-amino acid protein belonging to the ribosomal S10e family of proteins[@gerrish2000]:

| Feature | Details |
|---------|---------|
| Molecular weight | ~18.9 kDa |
| Structure | Alpha-helical fold with beta-sheet elements |
| rRNA interactions | Contacts 18S rRNA helix 16 |
| Protein interactions | Interacts with RPS20, RPS3 |

Structural domains:

• N-terminal region: Involved in rRNA binding
• C-terminal domain: Mediates interactions with other ribosomal proteins
• Surface residues: Form binding sites for translation factors

Role in Translation

RPS10 participates in several critical steps of protein synthesis:

Interaction Network

RPS10 interacts with several cellular proteins and pathways:

| Partner | Interaction | Functional Role |
|---------|-------------|-----------------|
| RPS20 | Direct contact | Ribosomal assembly |
| RPS3 | Direct contact | Translation fidelity |
| eIF2 | Factor binding | Initiation complex |
| p53 | Stress signaling | Apoptosis regulation |
| MDM2 | Ubiquitination | p53 degradation |

Role in Disease

Diamond-Blackfan Anemia

RPS10 mutations account for approximately 9% of DBA cases, making it one of the more common ribosomal protein genes mutated in this disorder[@blo2011][@cmejla2011]:

Genetics

• Inheritance: Autosomal dominant (most cases)
• Mutation types: Missense, nonsense, frameshift
• Hotspots: No clear mutation hotspots identified
• Penetrance: Variable (not all carriers develop DBA)

Pathogenesis

The mechanism by which RPS10 mutations cause DBA involves:

Clinical Features

| Feature | Description |
|---------|-------------|
| Anemia | Macrocytic, normochromic |
| Reticulocytopenia | Low reticulocyte count |
| Elevated eADA | Elevated erythrocyte adenosine deaminase |
| Congenital anomalies | ~30% have physical abnormalities |
| Cancer risk | Increased risk of AML, solid tumors |

Treatment

| Treatment | Mechanism | Notes |
|-----------|-----------|-------|
| Corticosteroids | Stimulate erythropoiesis | First-line; ~80% respond |
| Transfusions | Red blood cell support | For steroid non-responders |
| Iron chelation | Manage iron overload | Required with chronic transfusions |
| Stem cell transplant | Curative | For severe cases |

Alzheimer's Disease

Emerging evidence links RPS10 to AD pathogenesis through multiple mechanisms[@sanches2016]:

Translational Dysregulation

• Global translation: RPS10 dysfunction may contribute to the general translational impairment observed in AD brain
• Specific translation: Altered translation of specific mRNAs relevant to synaptic function
• Ribosome profiling: Studies show reduced ribosome occupancy on key neuronal transcripts in AD

Synaptic Dysfunction

• Synaptic proteins: Disrupted synthesis of synaptic proteins due to ribosomal deficits
• Long-term potentiation: Impaired LTP in models with ribosomal protein deficiency
• Memory consolidation: Role in protein synthesis-dependent memory formation

p53 Pathway Interactions

• p53 activation: Ribosomal stress can activate p53
• Apoptosis: Enhanced neuronal apoptosis in AD
• DNA damage: Interactions with DNA repair pathways

Parkinson's Disease

RPS10 dysfunction may contribute to PD through[@hersheson2019]:

Protein Synthesis Machinery

• Dopaminergic neurons: High protein synthesis demands make these neurons vulnerable
• Mitochondrial proteins: Impaired translation of proteins involved in mitochondrial function
• Synaptic maintenance: Disrupted synthesis of synaptic proteins

Cellular Stress

• ER stress: RPS10 deficiency can trigger unfolded protein response
• Oxidative stress: Interactions with oxidative stress pathways
• Autophagy: Ribosomal stress can activate autophagy pathways

Evidence from Studies

• PD patient brains show altered ribosomal protein expression
• Animal models demonstrate sensitivity to ribosomal protein deficiency
• LRRK2 mutations may affect ribosomal function

Cancer

RPS10 and other ribosomal proteins have been implicated in cancer:

• p53 pathway: Ribosomal stress can bypass MDM2-mediated p53 inhibition
• Cell proliferation: Altered translation affects cell cycle progression
• Metastasis: Ribosomal protein expression correlates with invasive capacity

Expression Pattern

Tissue Distribution

RPS10 is ubiquitously expressed across all tissues:

| Tissue | Expression Level |
|--------|-------------------|
| Bone marrow | High (erythropoietic cells) |
| Brain | High (neurons) |
| Heart | Moderate |
| Liver | Moderate |
| Kidney | Moderate |
| Skeletal muscle | Low-moderate |

Cellular Localization

• Cytoplasmic: Primarily in ribosomes
• Nuclear: Active ribosomal biogenesis in nucleolus
• Mitochondrial: Some association with mitochondrial ribosomes

Developmental Regulation

• Embryonic: High expression during development
• Postnatal: Reduced but maintained expression
• Cell-type specific: Higher in rapidly dividing cells

Therapeutic Implications

Diamond-Blackfan Anemia

Current and emerging therapies for DBA associated with RPS10:

| Approach | Status | Notes |
|----------|--------|-------|
| Corticosteroids | Standard of care | First-line therapy |
| L-leucine | Phase 2/3 trials | Amino acid that may stimulate erythropoiesis |
| Gene therapy | Preclinical | Potential for correcting mutations |
| Small molecules | Discovery | Targeting p53 pathway |

Neurodegenerative Diseases

RPS10 as a therapeutic target remains exploratory:

Small Molecules

• Translation modulators: Compounds that enhance or normalize translation
• p53 pathway modulators: Downstream of ribosomal stress

Gene Therapy

• Viral vectors: Deliver functional RPS10
• CRISPR: Potential for allele-specific correction

Combination Approaches

• Targeting both RPS10 and other ribosomal proteins
• Combining with neuroprotective strategies

Animal Models

Mouse Models

| Model | Phenotype | Relevance |
|-------|-----------|-----------|
| Rps10 knockout | Embryonic lethal | Essential gene |
| Rps10 heterozygous | Mild anemia, ribosome defects | DBA modeling |
| Conditional KO | Tissue-specific deficiency | Tissue-specific effects |
| Point mutations | DBA-associated mutations | Disease mechanisms |

Zebrafish Models

• Morpholino knockdown: Developmental defects
• CRISPR models: Phenocopy DBA
• Drug screening: Identify therapeutic compounds

Invertebrate Models

• Drosophila: RPS10 homolog in development
• C. elegans: Ribosomal protein function in neurons

Protein Interactions

Ribosomal Proteins

RPS10 forms a network of interactions within the 40S subunit:

• RPS20: Direct contact at the subunit interface
• RPS3: Located nearby in the 40S structure
• RPS14: Contact through the 18S rRNA

Translation Factors

RPS10 interacts with several translation initiation factors:

• eIF2: GTPase-activating protein complex component
• eIF3: Large initiation factor complex
• eIF4E: Cap-binding protein

Signaling Proteins

• p53: Tumor suppressor activated by ribosomal stress
• MDM2: E3 ubiquitin ligase that targets p53
• 4E-BP: eIF4E-binding protein regulated by mTOR

Clinical Significance

Diagnostic Testing

• Genetic testing: Sequencing of RPS10 coding region
• Functional assays: Ribosome biogenesis analysis
• Biomarkers: eADA levels, fetal hemoglobin

Prognostic Factors

• Mutation type: Missense vs truncating
• Response to steroids: Predicts long-term outcome
• Transfusion independence: Key outcome measure

Family Testing

• Carrier screening: For at-risk family members
• Prenatal testing: For known mutations
• Preimplantation diagnosis: For families seeking to avoid transmission

Population Genetics

Genetic Variation

| Variant Type | Frequency | Pathogenicity |
|--------------|-----------|---------------|
| Pathogenic mutations | Rare | DBA-causing |
| Variants of uncertain significance | Rare | Requires interpretation |
| Common polymorphisms | Common | Generally benign |

Disease Incidence

• DBA incidence: 5-15 per 100,000 live births
• RPS10 proportion: ~9% of DBA cases

Evolutionary Conservation

Species Conservation

RPS10 is highly conserved across eukaryotes:

| Species | Homology | Notes |
|---------|----------|-------|
| Human | 100% | Reference |
| Mouse | 99% | Highly similar |
| Zebrafish | 89% | Functional ortholog |
| Drosophila | 72% | Homolog |
| Yeast | 65% | S20 homolog |

See Also

• [Ribosomal Proteins](/entities/ribosomal-proteins)
• [Diamond-Blackfan Anemia](/diseases/diamond-blackfan-anemia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Protein Synthesis Pathway](/mechanisms/protein-synthesis)
• [Ribosome Biogenesis](/mechanisms/ribosome-biogenesis)
• [p53 Signaling Pathway](/mechanisms/p53-signaling)

Ribosomal Stress in Neurodegeneration

Cellular Stress Responses

Ribosomal dysfunction triggers comprehensive cellular stress responses:

Unfolded Protein Response (UPR)

RPS10 deficiency activates UPR pathways:

• PERK pathway: eIF2α phosphorylation reduces translation load
• IRE1 pathway: XBP1 splicing for chaperone expression
• ATF6 pathway: ATF6 cleavage and transcription activation

Integrated Stress Response (ISR)

The ISR coordinates stress responses:

Mitochondrial Connections

RPS10 dysfunction affects mitochondrial homeostasis:

| Process | Effect | Neuronal Impact |
|---------|--------|----------------|
| Mitochondrial protein synthesis | Impaired | Energy deficits |
| mtDNA translation | Reduced | Respiratory chain defects |
| Mitochondrial dynamics | Altered | Fission/fusion imbalance |
| Mitophagy | Reduced | Accumulation of damaged mitochondria |

Protein Homeostasis

Ribosomal stress disrupts proteostasis:

• Aggregate formation: Misfolded proteins accumulate
• Autophagy activation: Clearance mechanisms engaged
• Proteasome function: Enhanced degradation pathways

Neuroinflammation

Inflammatory Responses

Ribosomal dysfunction triggers neuroinflammation:

• Microglial activation: Pro-inflammatory cytokine release
• Cytokine cascades: IL-1β, TNF-α, IL-6 elevation
• Blood-brain barrier: Increased permeability

Neuroinflammatory Pathways

Therapeutic Implications

Targeting neuroinflammation in ribosomal dysfunction:

• Anti-inflammatory agents: Reduce microglial activation
• Translation enhancers: Restore protein synthesis
• Neuroprotective compounds: Support neuronal survival

Aging and Cellular Senescence

Senescence-Associated Changes

Ribosomal function declines with aging:

• Ribosome biogenesis: Reduced assembly capacity
• Translation fidelity: Increased error rates
• Ribosomal RNA: Epigenetic silencing

Interventions

Strategies to maintain ribosomal function:

• Caloric restriction: Improves ribosomal maintenance
• Rapamycin: mTOR inhibition enhances longevity
• Spermidine: Promotes autophagy and translation

Diagnostic Applications

Biomarker Potential

RPS10-related biomarkers:

| Biomarker | Source | Clinical Utility |
|-----------|--------|------------------|
| RPS10 protein levels | PBMCs, brain tissue | Disease progression |
| Ribosome assembly | Ribosomal profiling | Ribosomal function |
| p53 activation markers | Blood, CSF | Cellular stress |

Genetic Testing

Current testing approaches:

• Targeted sequencing: RPS10 coding region
• Panel testing: Ribosomal protein gene panels
• Whole exome: Comprehensive analysis

Clinical Trials and Therapeutics

Current Approaches

Active therapeutic strategies for ribosomal disorders:

Small Molecule Therapies

• L-leucine: Amino acid supplementation to stimulate translation
• Promoting ribosome biogenesis: Drug candidates in development
• p53 pathway modulators: Downstream targeting

Gene Therapy Approaches

• AAV vectors: RPS10 delivery to target tissues
• CRISPR editing: Correct pathogenic mutations
• RNA-based therapies: Splice-modulating approaches

Clinical Trial Status

| Approach | Phase | Status | Indication |
|----------|-------|--------|------------|
| L-leucine | 2/3 | Recruiting | DBA |
| Sotatercept | 2 | Active | DBA |
| CRISPR | Preclinical | Development | DBA |

Future Directions

Research Priorities

Key areas for future investigation:

Emerging Technologies

• Ribosome profiling: Single-cell resolution of translation
• CRISPR screening: Identifying genetic modifiers
• iPSC models: Patient-derived neuronal models

References

Pathway Diagram

The following diagram shows the key molecular relationships involving RPS10 Gene - Ribosomal Protein S10 discovered through SciDEX knowledge graph analysis: